<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0af69daf-c3eb-436a-b8d9-8ae89c5f0c85"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.<br/>
      <br/> BELEODAQ<sup>®</sup> (belinostat) for injection, for intravenous use<br/> Initial U.S. Approval: 2014</title>
   <effectiveTime value="20250407"/>
   <setId root="2e8ef36b-71fa-4492-a16f-577d5f7d111d"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="116965616"/>
            <name>Acrotech Biopharma Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="116965616" root="1.3.6.1.4.1.519.1"/>
                  <name>Acrotech Biopharma Inc</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="370088959" root="1.3.6.1.4.1.519.1"/>
                        <name>Cenexi-Laboratories Thissen S.A</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="098908572" root="1.3.6.1.4.1.519.1"/>
                        <name>AndersonBrecon Inc</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="124193793" root="1.3.6.1.4.1.519.1"/>
                        <name>Curia New York, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="59017e34-b372-49c9-bc38-6a9a33833705"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250407"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72893-002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Beleodaq<suffix/>
                        </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Belinostat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="10" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F4H96P17NZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BELINOSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="F4H96P17NZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BELINOSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1000" unit="mg"/>
                              <denominator value="10" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72893-002-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20140721"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA206256" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140721"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="rcm">
               <id root="b27dbdee-fa4c-4872-b185-447bac16a8af"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage and Administration (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.6">2.3</linkHtml>, <linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.7">2.4</linkHtml>, <linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.8">2.6</linkHtml>)                                                                                        11/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f">
               <id root="a3d80869-22e7-4c42-95cc-a0d169671e08"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).</paragraph>
                  <paragraph>This indication is approved under accelerated approval based on tumor response rate and duration of response [<content styleCode="italics">see Clinical Studies</content> (<content styleCode="italics">
                        <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</linkHtml>
                     </content>)]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).</paragraph>
                        <br/>
                        <paragraph> This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.(<linkHtml href="#i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476">
               <id root="024254cf-e44a-410a-9c8e-ca65de2b30d5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Recommended dosage of Beleodaq is 1,000 mg/m<sup>2</sup> administered over 30 minutes by intravenous infusion once daily on days 1 through 5 of a 21-day cycle. Cycles can be repeated until disease progression or unacceptable toxicity. (<linkHtml href="#i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac">2.1</linkHtml>)</item>
                           <item>Treatment discontinuation or interruption with or without dosage reductions by 25% may be needed to manage adverse reactions (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</linkHtml>)</item>
                           <item>Reduce dosage in patients with moderate hepatic or renal impairment. (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.6">2.3</linkHtml>, <linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.7">2.4</linkHtml>, <linkHtml href="#i4i_specific_populations_duplicate_id_8c25fb28-cfbd-489b-92f1-7a46d506ee2f">8.6</linkHtml>, <linkHtml href="#i4i_specific_populations_duplicate_id_9f086d02-a930-4b85-ad93-77a6aeec7a23">8.7</linkHtml>)</item>
                           <item>Avoid use in patients with severe hepatic or renal impairment. (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.6">2.3</linkHtml>, <linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.7">2.4</linkHtml>, <linkHtml href="#i4i_specific_populations_duplicate_id_8c25fb28-cfbd-489b-92f1-7a46d506ee2f">8.6</linkHtml>, <linkHtml href="#i4i_specific_populations_duplicate_id_9f086d02-a930-4b85-ad93-77a6aeec7a23">8.7</linkHtml>)</item>
                           <item>Modify dosage in patients known to be homozygous for the UGT1A1*28 allele. (<linkHtml href="#i4i_dosage_admin_duplicate_id_66ef38bd-654c-425e-8932-5a423a723d2f">2.5</linkHtml>)</item>
                           <item>See the full prescribing information for preparation and administration instructions. (<linkHtml href="#ID_9a204218-9064-4333-9d6d-52c5b5836041">2.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac">
                     <id root="c42c34b0-2740-4e97-885b-5b9c2660941f"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of Beleodaq is 1,000 mg/m<sup>2</sup> administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or unacceptable toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">
                     <id root="be1d50ca-498e-4d49-a4ab-7e366ef7e562"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosage Modification for Hematologic and Non-Hematologic Toxicities</title>
                     <text>
                        <paragraph>
                           <linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">Table 1</linkHtml>  displays the recommended Beleodaq dosage modifications for hematologic and non-hematologic toxicities. Base dosage adjustments for thrombocytopenia and neutropenia on platelet and absolute neutrophil nadir (lowest value) counts in the preceding cycle of  therapy.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <caption>•</caption>Absolute neutrophil count (ANC) should be greater than or equal to 1 x 10<sup>9</sup>/L and the platelet count should be greater than or equal to 50 x 10<sup>9</sup>/L prior to the start of each cycle and prior to resuming treatment following toxicity. Resume subsequent treatment with Beleodaq according to the guidelines described in <linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">Table 1</linkHtml> below. Discontinue Beleodaq in patients who have recurrent ANC nadirs less than 0.5 x 10<sup>9</sup>/L and/or recurrent platelet count nadirs less than 25 x 10<sup>9</sup>/L after two dosage reductions.</item>
                           <item>
                              <caption>•</caption>Other toxicities must be NCI-CTCAE Grade 2 or less prior to re-treatment.</item>
                        </list>
                        <paragraph>Monitor complete blood counts at baseline and weekly. Perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" ID="_RefID0EJBAC" width="100%">
                           <caption> Table 1: Dosage Modifications for Hematologic and Non-Hematologic Toxicities  
			</caption>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Rrule" align="center" valign="top">
                                    <content styleCode="bold">Dosage Modification</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" valign="middle">
                                    <content styleCode="bold"> Dosage Modifications due to Hematologic Toxicities</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Platelet count ≥ 25 x 10<sup>9</sup>/L and nadir ANC ≥ 0.5 x 10<sup>9</sup>/L<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">No Change<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Nadir ANC &lt; 0.5 x 10<sup>9</sup>/L (any platelet count)<br/>
                                 </td>
                                 <td styleCode="Rrule" rowspan="2" valign="middle">Decrease dosage by 25% (750 mg/m<sup>2</sup>)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Platelet count &lt; 25 x 10<sup>9</sup>/L (any nadir ANC)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" valign="middle">
                                    <content styleCode="bold"> Dosage Modifications due to Non-Hematologic Toxicities</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Any CTCAE Grade 3 or 4 adverse reaction<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">ª</linkHtml>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Decrease dosage by 25% (750 mg/m<sup>2</sup>)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Recurrence of CTCAE Grade 3 or 4 adverse reaction after two dosage reductions<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Discontinue Beleodaq<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>ªFor nausea, vomiting, and diarrhea, dose modification may not be necessary if the duration is less than 7 days with supportive management</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.6">
                     <id root="9041997d-ee6a-45ae-ba0b-2eafc64dedc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Recommended Dosage in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>Beleodaq dosage in patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 x ULN, any aspartate aminotransferase (AST)) is 500 mg/m<sup>2</sup> administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Avoid use of Beleodaq in patients with severe hepatic impairment (total bilirubin &gt; 3 x ULN, any AST). No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin ≤ 1.5 x ULN, any AST). Hepatic impairment is defined per the National Cancer Institute Organ Dysfunction Working Group.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.7">
                     <id root="346b0dac-b656-44b6-b475-5c7db8a99e28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Recommended Dosage in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Beleodaq dosage in patients with moderate renal impairment (creatinine clearance [CLcr] 30 to &lt;60 mL/min) is 500 mg/m<sup>2</sup> administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Avoid use of Beleodaq in patients with severe renal impairment (CLcr &lt; 30 mL/min). No dosage adjustment is recommended for patients with mild renal impairment (CLcr 60 to &lt; 90 mL/min).</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_duplicate_id_66ef38bd-654c-425e-8932-5a423a723d2f">
                     <id root="9e9f2a7d-8efd-4057-bc23-9061030d855f"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.5 Dosage Modification for Patients with Reduced UGT1A1 Activity</title>
                     <text>
                        <paragraph>Reduce the starting dose of Beleodaq to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c">12.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.8">
                     <id root="d856fb85-175f-4f05-b729-5c8a6a748f24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.6 Dosage Modification for Concomitant Use with UGT1A1 Inhibitors</title>
                     <text>
                        <paragraph>Avoid concomitant use of Beleodaq with UGT1A1 inhibitors. If concomitant use of a UGT1A1 inhibitor is unavoidable, reduce the Beleodaq dosage by 25% as shown in <linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.8">Table 2</linkHtml>.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <caption>Table 2: Dosage Modifications for Concomitant Use with a UGT1A1 Inhibitor 
			</caption>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Beleodaq Starting Dosage</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Beleodaq Modified Dosage</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">1,000 mg/m<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">750 mg/m<sup>2</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">750 mg/m<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">562.5 mg/m<sup>2</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">500 mg/m<sup>2</sup>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Interrupt Beleodaq treatment for the duration of UGT1A1 inhibitor use. After discontinuation of a UGT1A1 inhibitor of 5 half-lives, resume the Beleodaq dosage that was taken prior to initiating the UGT1A1 inhibitor.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a204218-9064-4333-9d6d-52c5b5836041">
                     <id root="986e4490-6917-453f-bf4b-c510041274f2"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.7 Preparation and Administration</title>
                     <text>
                        <paragraph>Beleodaq is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                        </paragraph>
                        <paragraph>Preparation:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Aseptically reconstitute each vial of Beleodaq by adding 9 mL of Sterile Water for Injection into the Beleodaq vial with a suitable syringe to achieve a concentration of 50 mg of belinostat per mL. Swirl the contents of the vial until there are no visible particles in the resulting solution. If not used immediately, the reconstituted product may be stored for up to 12 hours at room temperature (15°C to 25°C; 59°F to 77°F).<br/>
                              <br/>
                           </item>
                           <item>Aseptically withdraw the volume needed for the required dosage (based on the 50 mg/mL concentration and the patient’s BSA [m<sup>2</sup>]) and transfer to an infusion bag containing 250 mL of 0.9 % Sodium Chloride Injection. If not used immediately, the infusion bag with drug solution may be stored at room temperature (15°C to 25°C; 59°F to 77°F) for up to 36 hours including infusion time.<br/>
                              <br/>
                           </item>
                           <item>Visually inspect the solution for particulate matter. Do not use if cloudiness or particulates are observed.</item>
                        </list>
                        <paragraph>Administration:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Connect the infusion bag containing drug solution to an infusion set with a 0.22 micron in-line filter for administration.<br/>
                              <br/>
                           </item>
                           <item>Infuse intravenously over 30 minutes. If infusion site pain or other symptoms potentially attributable to the infusion occur, the infusion time may be extended to 45 minutes.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282">
               <id root="db8badfc-ff7f-4af8-924b-81341f856066"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For injection: 500 mg, lyophilized powder in single-dose vial for reconstitution</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 500 mg, lyophilized powder in single-dose vial for reconstitution (<content styleCode="italics">
                              <linkHtml href="#i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282">3</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8">
               <id root="da64e948-2601-4959-bce8-6e65cfdbb2d0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_precautions_id_4f5d1822-ea0a-4087-8d1a-b3de996531f7">
               <id root="295f69a9-b3ae-4a05-9363-72f792512779"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Hematologic Toxicity</content>: Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities. (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</linkHtml>, <linkHtml href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Infection</content>: Serious and fatal infections (e.g., pneumonia and sepsis) (<linkHtml href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Beleodaq may cause hepatic toxicity and liver function test abnormalities. Monitor liver function tests and omit or modify dosage for hepatic toxicities. (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</linkHtml>, <linkHtml href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Tumor lysis syndrome</content>: Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Gastrointestinal Toxicity</content>: Nausea, vomiting and diarrhea occur with Beleodaq and may require antiemetic and antidiarrheal medications (<linkHtml href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</linkHtml>).</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. (<linkHtml href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</linkHtml>)                  </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">
                     <id root="9aeacb08-d036-4e99-98ad-b855eb54d075"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Hematologic Toxicity</title>
                     <text>
                        <paragraph>Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</linkHtml>
                           </content>) and <content styleCode="italics">Adverse Reactions(<linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">
                     <id root="c619336a-bade-4484-9f74-e6d3697cfb7f"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Infections</title>
                     <text>
                        <paragraph>Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq. Do not administer Beleodaq to patients with an active infection. Patients with a history of extensive or intensive chemotherapy may be at higher risk of life threatening infections <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">
                     <id root="1a3662e9-5aed-4dbc-9d3c-8e3f8534ba01"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities <content styleCode="italics">[see Adverse Reactions</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>)]</content>. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue Beleodaq based on the severity of the hepatic toxicity<content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2)</linkHtml> and Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">
                     <id root="04b0c4ce-b17a-4c30-9f43-21a8c6519131"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.4 Tumor Lysis Syndrome</title>
                     <text>
                        <paragraph>Tumor lysis syndrome has occurred in Beleodaq-treated patients in the clinical trial of patients with relapsed or refractory PTCL <content styleCode="italics">[see</content> <content styleCode="italics">Clinical Studies</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</linkHtml>
                           </content>)<content styleCode="italics">]</content>. Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions <content styleCode="italics">[see</content> <content styleCode="italics">Adverse Reactions</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>
                           </content>)<content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">
                     <id root="59a53a27-988e-4237-aa0d-6419bd759a6d"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.5 Gastrointestinal Toxicity</title>
                     <text>
                        <paragraph>Nausea, vomiting and diarrhea occur with Beleodaq <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>)] </content>and may require the use of antiemetic and antidiarrheal medications.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">
                     <id root="9e130524-3462-4b77-a982-c8dadd44c89f"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.6 Embryo-fetal Toxicity</title>
                     <text>
                        <paragraph>Based on its mechanism of action and findings of genotoxicity, Beleodaq can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_mechanism_action_id_8e6ba92d-e3d3-4963-939c-29b326bbd4b3">12.1</linkHtml>) </content>and<content styleCode="italics"> Nonclinical Toxicology (<linkHtml href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</linkHtml>)]</content>. Advise pregnant women of the risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with Beleodaq and for 6 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9">8.1</linkHtml>, <linkHtml href="#i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574">8.3</linkHtml>)</content>
                           <content styleCode="italics">.</content> Advise males with female partners of reproductive potential to use effective contraception during treatment with Beleodaq and for 3 months after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0">
               <id root="454ca35d-9a9c-4c5e-9103-b90942f8a4b4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described in more detail in other sections of the prescribing information.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <caption>•</caption>Hematologic Toxicity <content styleCode="italics">[see Warnings and Precautions</content> (<content styleCode="italics">
                           <linkHtml href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Tumor Lysis Syndrome<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Gastrointestinal Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (&gt;25%) are nausea, fatigue, pyrexia, anemia, and vomiting. (<content styleCode="italics">
                              <linkHtml href="#i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0">6</linkHtml>
                           </content>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Acrotech Biopharma Inc at 1-888-292-9617 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">
                     <id root="48c15df0-a528-4c5f-a493-e86a8cc16297"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Beleodaq may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions in Patients with Peripheral T-Cell Lymphoma</content>
                        </paragraph>
                        <paragraph>The safety of Beleodaq was evaluated in 129 patients with relapsed or refractory PTCL in the single arm clinical trial in which patients were administered Beleodaq at a dosage of 1,000 mg/m<sup>2</sup> administered over 30 minutes by IV infusion once daily on Days 1 through 5 of a 21-day cycle <content styleCode="italics">[see Clinical Studies</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</linkHtml>
                           </content>)<content styleCode="italics">]</content>. The median duration of treatment was 2 cycles (range 1 – 33 cycles).</paragraph>
                        <paragraph>The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting <content styleCode="italics">[see Clinical Studies</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</linkHtml>
                           </content>)<content styleCode="italics">]</content>.                   <linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">Table 3</linkHtml> summarizes the adverse reactions regardless of causality from the trial in patients with relapsed or refractory PTCL.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" ID="_RefID0EXDAE" width="100%">
                           <caption>Table 3: Adverse Reactions Occurring in ≥ 10% of Patients with Relapsed or Refractory PTCL (NCI CTC Grade 1-4) 
			</caption>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Adverse Reactions</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Percentage of Patients (%)</content>
                                    <br/>
                                    <content styleCode="bold">(N=129)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Adverse Reactions</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">97</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">61</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">42<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">37<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pyrexia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">35<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Anemia <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">32<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Vomiting<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">29<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Constipation<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">23<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">23<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Dyspnea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">22<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Rash<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Peripheral Edema <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Cough<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">19<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Thrombocytopenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pruritus<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Chills<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Increased Blood Lactate Dehydrogenase <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Decreased Appetite<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">15<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Infusion Site Pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hypokalemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Prolonged QT <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Abdominal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hypotension<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Phlebitis<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Dizziness<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Note: Adverse reactions are listed by order of incidence in the “All Grades” category first, then by incidence in “the Grade 3 or 4” category; Measured by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0</paragraph>
                        <paragraph>
                           <content styleCode="underline">Serious Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Sixty-one patients (47.3%) experienced serious adverse reactions while taking Beleodaq or within 30 days after their last dose of Beleodaq. The most common serious adverse reactions (&gt; 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure. One treatment-related death associated with hepatic failure was reported in the trial.</paragraph>
                        <paragraph>One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure. A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq. ECG analysis did not identify QTc prolongation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Discontinuations due to Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Twenty-five patients (19.4%) discontinued treatment with Beleodaq due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dosage Modifications due to Adverse Reactions</content>
                        </paragraph>
                        <paragraph>In the trial, dosage adjustments due to adverse reactions occurred in 12% of Beleodaq-treated patients.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_interactions_id_456775d3-18a0-4b58-8d34-377cd2f5e7ee">
               <id root="22dc20dd-91ba-4001-bc63-dcd00ddfda42"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>UGT1A1 Inhibitors: Avoid use or modify dosage if use is unavoidable. (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.8">2.6</linkHtml>, <linkHtml href="#ID_a497571b-109d-4617-847a-56cac2dfd851">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_a497571b-109d-4617-847a-56cac2dfd851">
                     <id root="82cd3640-731e-4173-89f7-d12c4b38d35f"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.1 UGT1A1 Inhibitors</title>
                     <text>
                        <paragraph>Avoid concomitant administration of Beleodaq with UGT1A1inhibitors. If concomitant use of a UGT1A1 inhibitor is unavoidable, modify the Beleodaq dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.8">2.6</linkHtml>)]</content>.<br/>
                           <br/> Belinostat is primarily metabolized by UGT1A1. Concomitant use with a UGT1A1 inhibitor increases belinostat exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)]</content>, which may increase the risk of Beleodaq adverse reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad">
               <id root="a3146801-7e13-4164-bdfa-eecabe2387ec"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advised not to breastfeed. (<content styleCode="italics">
                              <linkHtml href="#i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad.8">8.2</linkHtml>
                           </content>
                           <content styleCode="italics">)<br/>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9">
                     <id root="f95d5d5e-4c49-40fd-99f6-e6b74f037548"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on its mechanism of action, Beleodaq can cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells <content styleCode="italics">[see </content>
                           <content styleCode="italics">Clinical Pharmacology</content>
                           <content styleCode="italics"> (<linkHtml href="#i4i_mechanism_action_id_8e6ba92d-e3d3-4963-939c-29b326bbd4b3">12.1</linkHtml>) </content>and<content styleCode="italics"> Nonclinical Toxicology (<linkHtml href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</linkHtml>)]</content>.  There are no available data on Beleodaq use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. No animal reproduction studies were conducted with Beleodaq. Advise pregnant women of the potential risk to a fetus. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad.8">
                     <id root="91b45f42-2caa-45ea-8ec2-2859ade256fd"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="Lactation Section"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of belinostat in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child<content styleCode="italics">,</content> advise patients that breastfeeding is not recommended during treatment with Beleodaq, and for 2 weeks after the last dose </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574">
                     <id root="7f1f099c-cbac-460e-9d85-2a03af08281d"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Beleodaq can cause embryo-fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9">8.1</linkHtml>)]</content>.<br/>
                           <content styleCode="underline">
                              <br/> Pregnancy Testing</content>
                           <br/> Pregnancy testing is recommended for females of reproductive potential prior to initiating Beleodaq.<br/>
                           <br/>
                           <content styleCode="underline">Contraception</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Females</content>
                           <br/> Advise females of reproductive potential to use effective contraception during treatment with Beleodaq and for 6 months after the last dose.<br/>   <br/>
                           <content styleCode="italics">Males</content>
                           <br/> Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with Beleodaq and for 3 months after the last dose [<content styleCode="italics">see Nonclinical Toxicology </content>(<content styleCode="italics">
                              <linkHtml href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</linkHtml>
                           </content>)].  <br/>
                           <br/>
                           <content styleCode="underline">Infertility</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Males</content>
                           <br/> Based on findings from animal studies, Beleodaq may impair male fertility. The reversibility of the effect on fertility is unknown [<content styleCode="italics">see Nonclinical Toxicology</content> (<content styleCode="italics">
                              <linkHtml href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</linkHtml>
                           </content>)].                </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_fc875ec0-c1a4-4690-b737-865272ba9472">
                     <id root="ed9d4b54-0c9c-4b91-aba4-a3ceacd9c1a3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Beleodaq in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_c27428be-56cb-4540-844a-37578fdfd2b2">
                     <id root="02ec3c51-f407-49d4-bdc5-10d355bddd07"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In the single-arm trial, 48% of patients (N = 62) were ≥ 65 years of age and 10% of patients (N=13) were ≥ 75 years of age [see Clinical Studies (14)]. The median age of the trial population was 63 years. Patients ≥ 65 years of age had a higher response rate to Beleodaq treatment than patients &lt; 65 years of age (36% versus 16%) while no meaningful differences in response rate were observed between patients ≥ 75 years of age and those &lt; 75 years of age. No clinically meaningful differences in serious adverse reactions were observed in patients based on age (&lt; 65 years compared with ≥ 65 years or &lt; 75 years of age compared with ≥ 75 years of age).</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_specific_populations_duplicate_id_8c25fb28-cfbd-489b-92f1-7a46d506ee2f">
                     <id root="5c363ce9-f18c-4c75-ad15-3af3c7e4fd64"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.6 Use in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph> No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin ≤ 1.5 x ULN, any AST). Reduce the Beleodaq dosage in patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 x ULN, any AST) [see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.6">2.3</linkHtml>)]. Avoid use of Beleodaq in patients with severe hepatic impairment (total bilirubin &gt; 3 x ULN, any AST)<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)]</content>.</paragraph>
                        <br/>
                        <paragraph>Belinostat is metabolized in the liver, moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 x ULN, any AST) and severe hepatic impairment (total bilirubin &gt; 3 x ULN, any AST) increases belinostat exposure [see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)], which may increase the risk of Beleodaq adverse reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_specific_populations_duplicate_id_9f086d02-a930-4b85-ad93-77a6aeec7a23">
                     <id root="88ed2581-31d7-48bd-b51f-d5b9bd1cb24d"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.7 Use in Patients with Renal Impairment</title>
                     <text>
                        <paragraph> No dosage adjustment is recommended for patients with mild renal impairment (CLcr 60 to &lt; 90 mL/min). Reduce the Beleodaq dosage in patients with moderate renal impairment (CLcr 30 to &lt;60 mL/min)<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476.7">2.4</linkHtml>)]</content>. Avoid use of Beleodaq in patients with severe renal impairment (CLcr &lt; 30 mL/min).</paragraph>
                        <br/>
                        <paragraph>Moderate renal impairment (CLcr 30 to &lt;60 mL/min) increases belinostat exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)]</content>, which may increase the risk of Beleodaq adverse reactions. The effect of severe renal impairment (CLcr &lt; 30 mL/min) on belinostat pharmacokinetics is unknown <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_24dd5315-f21c-484c-9b2a-547f9f42ac9a">
               <id root="f58eee6a-2562-4b6e-a7f3-635eb1d76d24"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician. The elimination half-life of belinostat is 1.1 hours <content styleCode="italics">[see Clinical Pharmacology</content> (<content styleCode="italics">
                        <linkHtml href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3)</linkHtml>]</content>. </paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_d8e21c3f-5354-456b-901e-210f62270c6b">
               <id root="e5e7049b-df46-4b4a-8013-0f7c9625a712"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Beleodaq is a histone deacetylase inhibitor with a sulfonamide-hydroxamide structure. The chemical name of belinostat is (2E)-<content styleCode="italics">N</content>-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide. The structural formula is as follows:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The molecular formula is C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S and the molecular weight is 318.35 g/mol.</paragraph>
                  <paragraph>Belinostat is a white to off-white powder. It is slightly soluble in distilled water (0.14 mg/mL) and polyethylene glycol 400 (about 1.5 mg/mL), and is freely soluble in ethanol (&gt; 200 mg/mL). The pKa values are 7.87 and 8.71 by potentiometry and 7.86 and 8.59 by UV.</paragraph>
                  <paragraph>Beleodaq (belinostat) for injection is supplied as a sterile lyophilized yellow powder containing 500 mg belinostat as the active ingredient. Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. The drug product is supplied in a single-dose clear glass vial with a coated stopper and aluminum crimp seal with “flip-off” cap. Beleodaq is intended for intravenous administration after reconstitution with 9 mL Sterile Water for injection, and the reconstituted solution is further diluted with 250 mL of sterile 0.9% Sodium Chloride injection prior to infusion <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476">2)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_3db12f71-0cfd-48c9-a69f-ff934e1a006f">
               <id root="43e8e555-9749-46ea-ba72-3ba19812fb33"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250407"/>
               <component>
                  <section ID="i4i_mechanism_action_id_8e6ba92d-e3d3-4963-939c-29b326bbd4b3">
                     <id root="06f1cc1a-63ed-4b0e-a659-1393a06f2bd6"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. <content styleCode="italics">In vitro</content>, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (&lt;250 nM).</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacodynamics_id_9a3135c6-b8ac-4597-97ba-48523e9a274e">
                     <id root="1ecbdd70-8473-4c92-ace3-70ec87c30354"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Belinostat exposure-response relationships and the time course of pharmacodynamic response are not fully characterized.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>Multiple clinical trials have been conducted with Beleodaq, in many of which ECG data were collected and analyzed by a central laboratory. Analysis of clinical ECG and belinostat plasma concentration data demonstrated no meaningful effect of Beleodaq on cardiac repolarization. None of the trials showed any clinically relevant changes caused by Beleodaq on heart rate, PR duration or QRS duration as measures of autonomic state, atrio-ventricular conduction or depolarization; there were no cases of Torsades de Pointes.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">
                     <id root="92fed61e-0ec7-4e0c-b991-e24dd4dc6924"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph> The pharmacokinetic characteristics of belinostat were analyzed from pooled data from phase 1/2 clinical studies that used doses of belinostat ranging from 150 to 1200 mg/m<sup>2</sup> (0.15 to 1.2 times the approved recommended dosage).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Distribution<br/>
                           </content>The mean belinostat volume of distribution approaches total body water, indicating that belinostat has limited body tissue distribution. <content styleCode="italics">In vitro</content> plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination<br/>
                           </content>Belinostat elimination half-life is 1.1 hours with a total mean plasma clearance of 1240 mL/min. The total clearance approximates average hepatic blood flow (1500 mL/min), suggesting high hepatic extraction (clearance being flow dependent).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism<br/>
                           </content>Belinostat is primarily metabolized by hepatic UGT1A1. Belinostat also undergoes hepatic metabolism by CYP2A6, CYP2C9, and CYP3A4 enzymes.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion<br/>
                           </content>Following a single dose of radiolabeled belinostat (100 μCi, 1500 mg) administered as a 30-minute intravenous infusion in patients with recurrent or progressive malignancy, fecal excretion accounted for a mean (± SD) of 9.7% (± 6.5%) of the administered radioactive belinostat dose over 168 hours. The mean (± SD) of the administered radioactive belinostat dose that was excreted in urine over 168 hours was 84.8% (± 9.8%), of which unchanged belinostat accounted for only 1.7%.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Specific Populations<br/>
                           </content>
                           <content styleCode="italics">Hepatic Impairment<br/>
                           </content>Belinostat steady state clearance decreased and AUC increased as a function of the degree of liver dysfunction, but were unchanged for C<sub>max</sub>, half‐life and apparent volume of distribution. Mean belinostat clearance was reduced by 18% in mild (total bilirubin ≤ ULN and AST &gt;ULN, or total bilirubin ˃1 to 1.5 x ULN), 24% in moderate (total bilirubin ˃ 1.5 to 3 times ULN and any value for AST) and 33% in severe hepatic impairment (total bilirubin ˃ 3 to 10 times ULN and any value for AST). Increases in belinostat exposure were correlated with worsening liver function, but there was no obvious relationship between exposure and DLTs during the first cycle of therapy.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment<br/>
                           </content>Belinostat C<sub>max </sub>increased by 1.7-fold, AUC<sub>0-∞</sub> by 1.3-fold and CL<sub>tot</sub> was unchanged in patients with mild renal impairment (CLcr 60 to &lt;90 ml/min). Belinostat C<sub>max</sub> and AUC<sub>0-∞</sub> increased by 1.7-fold and CL<sub>tot</sub> decreased by 26% in patients with moderate renal impairment (CLcr 30 &lt; 60 ml/min). The effect of severe renal impairment (CLcr &lt; 30 mL/min) on belinostat pharmacokinetics is unknown.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies<br/>
                           </content>Clinical Studies and Model-Informed Approaches<br/>
                           <content styleCode="italics">
                              <content styleCode="underline">UGT1A1 inhibitors</content>
                           </content>: Belinostat t<sub>1/2</sub> increased by 1.5-fold, AUC<sub>0-inf</sub> increased by 1.4-fold, C<sub>max </sub>decreased by 33%, and renal excretion increased by 2.5-fold following concomitant administration with atazanavir (UGT1A1 inhibitor), but there was minimal change in steady state clearance. There was minimal change in belinostat glucuronide C<sub>max</sub>, AUC<sub>0-24</sub>; however, belinostat glucuronide excretion decreased by 48%. </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Warfarin</content>
                           </content>: No clinically significant differences in the pharmacokinetics of R- or S-warfarin were observed when used concomitantly with belinostat.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content> <br/>
                           <content styleCode="italics">
                              <content styleCode="underline">CYP450 Enzymes</content>
                           </content>: Belinostat and its metabolites are CYP2C8 and CYP2C9 inhibitors.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Transporter Systems</content>
                           </content>: Belinostat is a glycoprotein (P-gp) substrate but is not a P-gp inhibitor.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c">
                     <id root="45064668-600f-475e-857a-d625685fc550"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 20% of the Black population, 10% of the White population, and 2% of the Asian population are homozygous for the UGT1A1*28 allele. Additional reduced function alleles may be more prevalent in specific populations.</paragraph>
                        <paragraph>Because belinostat is primarily (80 -90%) metabolized by UGT1A1, the clearance of belinostat could be decreased in patients with reduced UGT1A1 activity (e.g., patients with UGT1A1*28 allele). Reduce the starting dose of Beleodaq to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_dosage_admin_duplicate_id_66ef38bd-654c-425e-8932-5a423a723d2f">2.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_nonclinical_toxicology_id_2e570443-2e43-4d3d-a022-36529932ec42">
               <id root="bc752d04-c87f-4185-901c-47a07ded0d60"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250407"/>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">
                     <id root="91ab4af3-acc1-4c00-9a62-ad945ec2d182"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been performed with belinostat.</paragraph>
                        <paragraph>Belinostat was genotoxic in a bacterial reverse mutation test (AMES assay), an in vitro mouse lymphoma cell mutagenesis assay, and an in vivo rat micronucleus assay. </paragraph>
                        <paragraph>Beleodaq may impair male fertility. Fertility studies using belinostat were not conducted. However, belinostat effects on male reproductive organs observed during the 24-week repeat-dose dog toxicology study included reduced organ weights of the testes/epididymides that correlated with a delay in testicular maturation.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">
               <id root="8295f691-568c-44fb-a1c5-f8e59635c57f"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)</content>
                  </paragraph>
                  <paragraph>In an open-label, single-arm, non-randomized international trial conducted at 62 centers, 129 patients with relapsed or refractory PTCL were treated with Beleodaq 1,000 mg/m<sup>2</sup> administered over 30 minutes via IV infusion once daily on Days 1 through 5 of a 21-day cycle. There were 120 patients who had histologically confirmed PTCL by central review evaluable for efficacy. Patients were treated with repeat cycles every three weeks until disease progression or unacceptable toxicity.</paragraph>
                  <paragraph>Efficacy was evaluated using response rate (complete response and partial response) as assessed by an independent review committee (IRC) using the International Workshop Criteria (IWC) (Cheson 2007). Response assessments were evaluated every 6 weeks for the first 12 months and then every 12 weeks until 2 years from the start of study treatment. Duration of response was measured from the first day of documented response to disease progression or death. Response and progression of disease were evaluated by the IRC using the IWC.</paragraph>
                  <paragraph>
                     <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">Table 4</linkHtml> summarizes the baseline demographic and disease characteristics of the study population, who were evaluable for efficacy.</paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" ID="_RefID991E21B9E3224CD4AB1EBFB4881FA21E" width="100%">
                     <caption>Table 4 Baseline Patient Characteristics (PTCL Population) 			 			 			 
			</caption>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">
                              <content styleCode="bold">Characteristics</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Evaluable Patients</content>
                              <br/>
                              <content styleCode="bold">(N=120)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> Age (years)<br/>                  Median (range)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">64 (29-81)<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> Sex, %<br/>                  Male<br/>                  Female<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">52<br/>             48<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> Race, %<br/>                  White<br/>                  Black<br/>                  Asian<br/>                  Latin<br/>                  Other<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">88<br/>             6<br/>             3<br/>             3<br/>             2<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> PTCL Subtype Based on Central Diagnosis, %<br/>                  PTCL Unspecified (NOS)<br/>                  Angioimmunoblastic T-cell lymphoma (AITL)<br/>                  ALK-1 negative anaplastic large cell lymphoma (ALCL)<br/>                  Other<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">64<br/>             18<br/>             11<br/>             7<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> Baseline Platelet Count, %<br/>                  ≥100,000/μL<br/>                  &lt;100,000/μL<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">83<br/>             17<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom"> ECOG Performance Status, %<br/>                  0<br/>                  1<br/>                  2<br/>                  3<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">34<br/>             43<br/>             22<br/>             1<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top"> Median Time (months) from Initial PTCL Diagnosis (Range)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">12 (2.6 - 266.4)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top"> Median Number of Prior Systemic Therapies (Range)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">2 (1-8)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In all evaluable patients (N = 120) treated with Beleodaq, the overall response rate per central review using IWC was 25.8% (N = 31) (              <linkHtml href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">Table 5</linkHtml> ) with rates of 23.4% for PTCL, NOS and 45.5% for AITL, the two largest subtypes enrolled. </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" ID="_RefID6F802A4E4EF345BDB8C7891823F5598D" width="40%">
                     <caption>Table 5: Response Analysis per Central Assessment Using IWC in Patients with Relapsed or Refractory PTCL 			 			 			 
			</caption>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle"/>
                           <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                              <content styleCode="bold">Evaluable Patients</content>
                              <br/>
                              <content styleCode="bold">(N=120)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="bottom">
                              <content styleCode="bold"> Response Rate</content>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">
                              <content styleCode="bold">N (%)</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="bottom">
                              <content styleCode="bold">(95% CI)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <caption> </caption>CR+PR</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">31 (25.8)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">18.3-34.6<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <caption> </caption>CR</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">13 (10.8)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">5.9-17.8<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <caption> </caption>PR</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">18 (15.0)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">9.1-22.7<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>CI=confidence interval, CR=complete response, PR=partial response</paragraph>
                  <paragraph>The median duration of response based on the first date of response to disease progression or death was 8.4 months (95% CI: 4.5 - 29.4). Of the responders, the median time to response was 5.6 weeks (range 4.3 - 50.4 weeks). Nine patients (7.5%) were able to proceed to a stem cell transplant after treatment with Beleodaq.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="i4i_references_id_60003015-7603-4806-bdf0-b0e4ba2e15cd">
               <id root="3ff7307b-7da6-4ab0-9a99-7f6403ead89f"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>
                     <sup>1</sup> OSHA Hazardous Drugs. <content styleCode="italics">OSHA</content>.  http://www.osha.gov/SLTC/hazardousdrugs/index.html            </paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_5e08debb-9ee1-4da3-a2f7-7953e5276de4">
               <id root="1a3d3c9c-aa6a-4d5e-906d-e3976deb07dc"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                     <br/> Beleodaq (belinostat) for injection is supplied in single vial cartons; each clear vial contains sterile, lyophilized powder equivalent to 500 mg belinostat.<br/>
                     <br/> NDC 72893-002-01: Individual carton of Beleodaq single-dose vial containing 500 mg belinostat.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store Beleodaq (belinostat) for injection at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Retain in original package until use. [see USP Controlled Room Temperature].<br/>
                     <br/> Beleodaq is a hazardous drug.Follow special handling and disposal procedures.<sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="i4i_info_patients_id_9fb597bb-e1a3-4e33-ab47-f9285b5029f2">
               <id root="79f32edd-cb55-4b3b-acd2-93da95439346"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>              Physicians should discuss the FDA approved Patient Information Leaflet with patients prior to treatment with Beleodaq. Instruct patients to read the Patient Information Leaflet carefully.<br/>
                     <br/> Advise the patient or the caregiver to read the FDA-approved patient labeling (Patient Information).<br/>
                     <br/> Advise patients or their caregivers:            </paragraph>
                  <br/>
                  <list listType="unordered" styleCode="disc">
                     <item>                To report symptoms of nausea, vomiting and diarrhea so that appropriate antiemetic and antidiarrheal medications can be administered [see <content styleCode="italics">                  Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</linkHtml>)                </content>].              </item>
                  </list>
                  <list listType="unordered" styleCode="disc">
                     <item>                To report any symptoms of thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia [see <content styleCode="italics">                  Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</linkHtml>)                </content>].              </item>
                  </list>
                  <list listType="unordered" styleCode="disc">
                     <item>                To immediately report symptoms of infection (e.g., pyrexia) [see <content styleCode="italics">                  Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</linkHtml>) and Adverse Reactions (<linkHtml href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</linkHtml>)                </content>].              </item>
                  </list>
                  <list listType="unordered" styleCode="disc">
                     <item>Of the potential risk to the fetus and for women to avoid pregnancy and use effective contraception while receiving Beleodaq and for 6 months after the last dose [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</linkHtml>)</content>]. Advise males with female partners of reproductive potential to use effective contraception during treatment with Beleodaq and for 3 months after the last dose.</item>
                  </list>
                  <list listType="unordered" styleCode="disc">
                     <item>                To avoid breastfeeding while receiving Beleodaq and for 2 weeks after the last dose [see <content styleCode="italics">                  Use in Specific Populations (<linkHtml href="#i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad.8">8.2</linkHtml>)                </content>].              </item>
                  </list>
                  <list listType="unordered" styleCode="disc">
                     <item>                To understand the importance of monitoring liver function test abnormalities and to immediately report potential symptoms of liver injury [see <content styleCode="italics">                  Dosage and Administration (<linkHtml href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</linkHtml>) and Warnings and Precautions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</linkHtml>)                </content>].              </item>
                  </list>
                  <paragraph>              Manufactured by:<br/> Cenexi Laboratories Thissen SA<br/> Braine I'Alleud, 1420, Belgium<br/>
                     <br/> Manufactured for:<br/> Acrotech Biopharma Inc<br/> East Windsor, NJ 08520 USA<br/>
                     <br/> Beleodaq is a registered trademark of Acrotech Biopharma Inc. All rights are reserved.<br/> U.S. Patent: 6,888,027            </paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="ID_87ad9416-0663-4f1b-80c3-ff7b2368b135">
               <id root="14638ada-d1cc-4499-9fb4-87f19210c2d6"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>SPL PATIENT PACKAGE INSERT SECTION</title>
               <text>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="976">
                     <colgroup/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="top">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">BELEODAQ<sup>®</sup>
                              </content>(Bē-lēo-dak)<content styleCode="bold">
                                 <br/>             (belinostat) for injection, for intravenous use</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Read this Patient Information before you receive treatment with Beleodaq and each time you receive Beleodaq. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What is Beleodaq?</content>
                              <br/>             Beleodaq is a prescription medicine used to treat people with a type of cancer called peripheral T-cell Lymphoma (PTCL) that comes back or does not respond to cancer treatment. <br/>             It is not known if Beleodaq is safe and effective in children.<content styleCode="bold">
                                 <br/>
                              </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold"> What should I tell my doctor before receiving Beleodaq?</content>
                              <br/>
                              <content styleCode="bold">Before receiving Beleodaq, tell your doctor about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>have an infection</item>
                                 <item>have had chemotherapy treatment</item>
                                 <item>have liver or kidney problems</item>
                                 <item>have nausea, vomiting, or diarrhea</item>
                                 <item>are pregnant or plan to become pregnant. Beleodaq can harm your unborn baby. You should not become pregnant while receiving Beleodaq. Tell your doctor right away if you become pregnant while receiving Beleodaq.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if Beleodaq passes into your breast milk. You and your doctor should decide if you will receive Beleodaq or breastfeed. You should not do both. </item>
                              </list>
                              <content styleCode="bold">Tell your doctor about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. <content styleCode="bold">
                                 <br/>
                              </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold"> How will I receive Beleodaq?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Beleodaq will be given to you by intravenous (IV) injection into your vein, usually over 30 minutes.</item>
                                 <item>Beleodaq is given one time a day on Days 1 through 5 of a 21-day cycle of treatment.</item>
                                 <item>You should have regular blood tests before and during your treatment with Beleodaq. </item>
                                 <item>Your doctor may change your dose of Beleodaq, change when you receive your treatment, or stop treatment if you have certain side effects while receiving Beleodaq.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">What are the possible side effects of Beleodaq?<br/>             Beleodaq may cause serious side effects, including:<br/>
                              </content>
                              <br/>             • <content styleCode="bold">Low blood cell counts.</content> Your doctor will do blood tests to check your blood counts during your treatment with Beleodaq.<br/>                 o <content styleCode="bold">Low platelet counts</content> can cause unusual bleeding or bruising under your skin.<br/>                 o <content styleCode="bold">Low red blood cell counts</content> may make you feel weak, tired, or you get tired easily, you look pale, or you feel short of breath.<br/>                 o <content styleCode="bold">Low white blood cell counts</content> can cause you to get infections, which may be serious.<br/>
                              <br/>             • <content styleCode="bold">Serious infections.</content> People receiving Beleodaq may develop serious infections that can sometimes lead to death. You may have a greater risk of life-threatening infections if you have had chemotherapy in the past. Tell your doctor right away if you have any of the following signs or symptoms of an infection: fever, flu-like symptoms, cough, shortness of breath, burning with urination, muscle aches, or worsening skin problems.<br/>
                              <br/>             • <content styleCode="bold">Liver problems.</content> Beleodaq may cause liver problems which can lead to death. Your doctor will do blood tests during your treatment with Beleodaq to check for liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems: yellowing of the skin or the white part of your eyes (jaundice), dark urine, itching, or pain in the right upper stomach area.<br/>
                              <br/>             • <content styleCode="bold">Tumor Lysis Syndrome (TLS).</content> TLS is caused by a fast breakdown of cancer cells. Your doctor will check you for TLS during treatment with Beleodaq.<br/>
                              <br/>             • <content styleCode="bold">Nausea, vomiting, and diarrhea</content> are common with Beleodaq and can sometimes be serious. Tell your doctor if you develop nausea, vomiting or diarrhea. Your doctor may prescribe medicines to help prevent or treat these side effects.<br/>
                              <content styleCode="bold">Common side effects of Beleodaq include</content> fatigue, fever, and low red blood cell count. Tell your doctor if you have any side effect that bothers you or that does not go away.<br/>             These are not all the possible side effects of Beleodaq. Call your doctor for medical advice about side effects. You can report side effects to FDA at 1-800-FDA-1088. <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">General information about Beleodaq</content>
                              <br/>             Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or doctor for information about Beleodaq that is written for health professionals.<content styleCode="bold">
                                 <br/>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold"> What are the ingredients in Beleodaq?</content>
                              <br/>             Active ingredient: belinostat<br/>             Inactive ingredients: L-Arginine<br/>
                              <content styleCode="bold">
                                 <br/>
                              </content>Manufactured by: Cenexi Laboratories Thissen SA, Braine I'Alleud, 1420, Belgium<br/>             Manufactured for: Acrotech Biopharma Inc, East Windsor, NJ 08520 USA<br/>             Beleodaq is a registered trademark of Acrotech Biopharma Inc. All rights reserved. <br/>             For more information, go to www.Beleodaq.com or call 1-888-292-9617.<content styleCode="bold">
                                 <content styleCode="bold">
                                    <br/>
                                 </content>
                              </content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                     Revised: Apr 2025</paragraph>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_d54f1a13-ad9b-415f-ac53-ec00b656d096">
               <id root="87263d9a-eaa3-40d8-82ee-04c2d807c7d6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <br/>
                  <paragraph>Carton Label</paragraph>
                  <paragraph>NDC 72893-002-01</paragraph>
                  <paragraph>Beleodaq® (belinostat) for injection</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph>For Intravenous Infusion Only</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <br/>
                  <paragraph>  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>Vial Label</paragraph>
                  <paragraph>NDC 72893-002-01<br/> Beleodaq® (belinostat) for injection</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph>For Intravenous Infusion Only</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>vial label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>